From March through December 2020, 100 autopsies were performed (Semmelweis University,
Budapest, Hungary), with chart review, of patients with severe acute respiratory syndrome …

Convalescent plasma therapy might be a feasible option for treatment of novel infections.
During the early phases of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2…

Large randomized clinical trials in severe Coronavirus Disease 2019 (COVID-19) patients
have proven efficacy of intravenous tocilizumab. Our aim was to describe the laboratory …

Objectives Our aim was to compare outcomes of hospitalized adults with severe COVID-19
and cytokine storm treated with tocilizumab or baricitinib. Methods A prospective, …

Data suggests that favipiravir (FVP) could be used against SARS-CoV-2. Our aim was to
investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was …

Emerging evidence suggests that remdesivir might improve clinical outcome of high-risk
outpatients with coronavirus disease 2019 (COVID-19). Our aim was to evaluate characteristics …

Baricitinib is considered a first-line treatment for severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm syndrome (…

Background Preliminary data suggests that favipiravir might have a role in COVID-19 treatment.
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods A …

Objectives Emerging evidence suggests that remdesivir might improve clinical outcome of
high-risk outpatients with COVID-19. Our aim was to evaluate characteristics and outcomes of …

Background: Preliminary data suggests that favipiravir might have a role in COVID-19 treatment.
Our aim was to assess the role of favipiravir in the treatment of COVID-19. Methods: A …